| UHC UMR Medical and Drug | Briumvi® (Ublituximab-Xiiy) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Clotting Factors, Coagulant Blood Products, & Other Hemostatics - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Collagen Crosslinks and Biochemical Markers of Bone Turnover – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Complement Inhibitors – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Discogenic Pain Treatment – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Elective Inpatient Services - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Electrical and Ultrasound Bone Growth Stimulators - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Elevidys® (Delandistrogene Moxparvovec-Rokl) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Epiduroscopy, Epidural Lysis of Adhesions, and Discography – Commercial and Individual Exchange Medical Policy | 2026-01-01 |